Sanofi Stock

Sanofi EBIT

The EBIT of Sanofi (SAN.PA) as of Aug 16, 2026 is 9.60 B EUR. In the previous year, EBIT was 8.87 B EUR — a change of 8.21% (higher).

EBIT

9.60 BEUR

YoY

8.21%

Last updated:

In 2026, Sanofi's EBIT was 9.60 B EUR, a 8.21% increase from the 8.87 B EUR EBIT recorded in the previous year.

The Sanofi EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B EUR)
Date
EBIT (B EUR)
Jan 1, 2023
8.12 base
Jan 1, 2024
8.87 base
Jan 1, 2025
9.60 base
Jan 1, 2026 (e)
9.90 base
Jan 1, 2027 (e)
10.51 base
Jan 1, 2028 (e)
11.02 base
Jan 1, 2029 (e)
11.45 base
Jan 1, 2030 (e)
11.95 base
YEAREBIT (B EUR)
2030 est 11.95
2029 est 11.45
2028 est 11.02
2027 est 10.51
2026 est 9.90
2025 9.60
2024 8.87
2023 8.12
2022 10.38
2021 8.13
2020 7.58
2019 3.05
2018 4.95
2017 5.80
2016 6.53
2015 5.62
2014 6.06
2013 4.98
2012 7.97
2011 5.73
2010 5.96
2009 6.37
2008 9.76
2007 5.92
2006 5.73
Access this data via the Eulerpool API

Sanofi Revenue

Sanofi Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
41.11 B EUR
8.12 B EUR
5.40 B EUR
Jan 1, 2024
44.29 B EUR
8.87 B EUR
5.56 B EUR
Jan 1, 2025
46.72 B EUR
9.60 B EUR
7.81 B EUR
Jan 1, 2026 (e)
47.51 B EUR
9.90 B EUR
10.46 B EUR
Jan 1, 2027 (e)
50.61 B EUR
10.51 B EUR
11.04 B EUR
Jan 1, 2028 (e)
54.02 B EUR
11.02 B EUR
12.03 B EUR
Jan 1, 2029 (e)
56.17 B EUR
11.45 B EUR
13.43 B EUR
Jan 1, 2030 (e)
58.60 B EUR
11.95 B EUR
14.55 B EUR

Sanofi Margins

Sanofi stock margins

The Sanofi margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sanofi. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sanofi.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
69.30 %
19.75 %
13.14 %
Jan 1, 2024
70.21 %
20.03 %
12.55 %
Jan 1, 2025
72.07 %
20.54 %
16.72 %
Jan 1, 2026 (e)
72.07 %
20.84 %
22.01 %
Jan 1, 2027 (e)
72.07 %
20.76 %
21.81 %
Jan 1, 2028 (e)
72.07 %
20.39 %
22.27 %
Jan 1, 2029 (e)
72.07 %
20.39 %
23.91 %
Jan 1, 2030 (e)
72.07 %
20.39 %
24.84 %

Sanofi Stock analysis

What does Sanofi do? Sanofi SA is a French company that was formed in 1973 from a merger of two French pharmaceutical and biotechnology companies. It is one of the largest players in the healthcare industry worldwide and employs over 100,000 employees. The objective of Sanofi is to improve people's lives through innovative medicines and therapies. In this regard, the company pursues a comprehensive business model that focuses on both research and development, as well as the production and distribution of medications and vaccines. The company has different divisions and product lines, which are divided into three business areas: Innovative Medicine, Consumer Healthcare, and Generic Pharmaceuticals. Innovative Medicine utilizes state-of-the-art technologies and scientific knowledge to treat the most challenging diseases. In the area of Consumer Healthcare, the company offers a wide range of over-the-counter products such as vitamins, dietary supplements, cough and cold remedies, as well as oral and dental health products. In the Generic Pharmaceuticals field, the company produces more cost-effective alternatives to expensive brand-name products, providing a variety of generic medications. Sanofi is a leading manufacturer of medications that are of great significance in various areas such as diabetes, oncology, cardiovascular diseases, and neurology. In recent years, the company has also established a strong presence in the field of vaccines. Here, Sanofi develops and produces innovative vaccines against COVID-19, influenza, and other infectious diseases. Sanofi is present in more than 170 countries and collaborates closely with physicians, research institutions, and health authorities to improve healthcare worldwide. The company conducts research and development in various disciplines and invests a significant amount each year in the development of innovative medicines and therapies. Overall, Sanofi SA is an emerging company in the pharmaceutical and healthcare sector. The portfolio of products and therapies offered by Sanofi is extensive and covers many areas of healthcare. Sanofi relies on continuous innovation and continuously works to improve healthcare and enhance the lives of people worldwide. Sanofi is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Sanofi's EBIT

Sanofi's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Sanofi's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Sanofi's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Sanofi’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Sanofi stock

EBIT of Sanofi is 9.60 B EUR in 2026.

EBIT of Sanofi changed from 8.87 B EUR to 9.60 B EUR, representing a 8.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Sanofi since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Sanofi historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Sanofi

All Key Metrics — Sanofi